BioNTech has completed its exchange offer to acquire CureVac

BioNTech已完成其收购CureVac的要约交换。

Acquisition complements BioNTech’s capabilities and proprietary technologies in mRNA design, delivery formulations, and mRNA manufacturing

收购补充了BioNTech在mRNA设计、递送配方和mRNA制造方面的能力和专有技术。

In total, approximately 86.75% of CureVac shares were tendered; BioNTech expects to complete the compulsory acquisition of the remaining CureVac shares in January 2026 as part of the previously announced post-offer reorganization

总计约有86.75%的CureVac股份被收购；BioNTech预计将在2026年1月完成对剩余CureVac股份的强制收购，作为此前宣布的要约后重组的一部分。

CureVac will continue to operate under its existing organizational processes, while BioNTech will conclude the strategic, operational, and scientific analyses required to define the future organizational and portfolio setup

CureVac 将继续在其现有的组织流程下运营，而 BioNTech 将完成定义未来组织和产品组合设置所需的战略、运营和科学分析。

MAINZ, Germany, December 18, 2025

德国美因茨，2025年12月18日

–

–

BioNTech SE

生物恩泰克股份公司

(Nasdaq: BNTX, “BioNTech”, or “the Company”) today announced the closing of its acquisition of CureVac N.V. (Nasdaq: CVAC, “CureVac”) and that the subsequent offering period (the “Subsequent Offering Period”) of the exchange offer (the “Offer”) for all outstanding shares of CureVac expired today at 12:01 a.m.

（纳斯达克：BNTX，“BioNTech”或“公司”）今天宣布完成了对CureVac N.V.（纳斯达克：CVAC，“CureVac”）的收购，并表示针对CureVac所有已发行股份的交换要约（“要约”）的后续要约期（“后续要约期”）已于今日凌晨12:01到期。

Eastern Time. With the successful acquisition, BioNTech intends to further complement its capabilities and proprietary technologies in mRNA design, delivery formulations, and mRNA manufacturing. The acquisition builds on BioNTech’s proven track record and established position in the global mRNA industry and supports the execution of the Company’s oncology strategy which focuses on two pan-tumor programs: mRNA-based cancer immunotherapy candidates, and pumitamig (BNT327/BMS986545), a bispecific antibody candidate targeting PD-L1 and VEGF-A, which is being jointly developed with Bristol Myers Squibb Company (NYSE: BMY, “BMS”)..

美国东部时间。通过此次成功收购，BioNTech 旨在进一步完善其在 mRNA 设计、递送配方和 mRNA 制造方面的能力和专有技术。此次收购基于 BioNTech 在全球 mRNA 行业中经过验证的业绩记录和已确立的地位，并支持公司执行其肿瘤学战略，该战略聚焦于两大泛肿瘤项目：基于 mRNA 的癌症免疫治疗候选药物，以及 pumitamig（BNT327/BMS986545），一种靶向 PD-L1 和 VEGF-A 的双特异性抗体候选药物，该药物正与百时美施贵宝公司（纽约证券交易所代码：BMY，“BMS”）联合开发。

“I want to thank everyone who helped make this transaction a success. It deepens our mRNA technology platform and offers potential to expand the ways we can develop mRNA as a new therapeutic drug class,” said

“我要感谢所有帮助促成这笔交易取得成功的人。这加深了我们的mRNA技术平台，并提供了扩展我们开发mRNA作为新治疗药物类别的潜力，”表示

Prof. Ugur Sahin, M.D.,

乌古尔·萨欣教授，医学博士，

CEO and Co-Founder of BioNTech

BioNTech的首席执行官兼联合创始人

. “With an approved mRNA product and multiple late-stage programs spanning distinct mechanisms of action, we are advancing a new generation of medicines aimed at delivering meaningful benefits for patients.”

“凭借一款获批的mRNA产品和覆盖不同作用机制的多个后期项目，我们正在推进新一代药物，旨在为患者带来显著益处。”

“With this acquisition, the pioneering efforts of two of Germany’s early mRNA firms are being brought together – a synergy of vision and technology. It is no coincidence that both originated in Germany, backed by dedicated long-term oriented family offices with an entrepreneurial spirit such as ATHOS KG and the dievini Hopp BioTech holding,” said .

“通过此次收购，德国两家早期mRNA公司的开创性努力将结合在一起——这是一种愿景与技术的协同效应。两家公司都源自德国，并受到具有创业精神、专注长期发展的家族办公室如ATHOS KG和dievini Hopp BioTech控股的支持，这并非巧合，”他表示。

Helmut Jeggle, Chairman of the BioNTech Supervisory Board

生物技术公司监事会主席赫尔穆特·耶格尔

. “This transaction has significant potential to contribute to the country’s innovation agenda to shape, not just follow, the next wave of innovation with global impact.”

“这笔交易有巨大的潜力，可以为国家的创新议程做出贡献，不仅能够塑造下一波具有全球影响力的创新，更能引领潮流。”

Following the closing of the acquisition, Prof. Ugur Sahin, M.D., Sierk Poetting, Ph.D., and Ramón Zapata-Gomez will constitute the Management Board of CureVac SE as the former members of the CureVac SE Management Board voluntarily resigned from their positions. CureVac will maintain its existing organizational processes to ensure a seamless continuity of its business, while BioNTech will conclude the strategic, operational and scientific analyses required to define the future organizational and portfolio setup.

在收购完成后，乌古尔·萨欣教授（医学博士）、西尔克·波廷（哲学博士）和拉蒙·扎帕塔-戈麦斯将组成 CureVac SE 的管理委员会，此前的 CureVac SE 管理委员会成员已自愿辞去职务。CureVac 将保留其现有的组织流程，以确保业务的无缝连续性，而 BioNTech 将完成必要的战略、运营和科学分析，以确定未来的组织架构和产品组合设置。

.

。

BioNTech was informed by Computershare Trust Company, N.A., the exchange agent for the Offer, that, as of the expiration time of the Subsequent Offering Period, a total of 195,341,219 CureVac shares, collectively representing approximately 86.75% of CureVac’s issued and outstanding shares, were validly tendered in the Offer.

BioNTech 获悉，作为要约交换代理的 Computershare Trust Company, N.A. 表示，在后续要约期满时，总计 195,341,219 股 CureVac 股份已有效提交要约，约占 CureVac 已发行和流通股份总数的 86.75%。

The Company expects to complete the compulsory acquisition of the remaining CureVac shares in January 2026 as part of the previously announced post-offer reorganization. CureVac shares will no longer be available for trading following the post-offer reorganization..

公司预计将于2026年1月完成对剩余CureVac股份的强制收购，这是此前宣布的要约后重组计划的一部分。在要约后重组完成后，CureVac股份将不再进行交易。

Further information on the Offer, including the post-offer reorganization, was previously laid out in BioNTech press releases issued on

有关该要约的更多信息，包括要约后的重组，此前已在BioNTech发布的新闻稿中列出。

November 26, 2025

2025年11月26日

and

和

December 3, 2025

2025年12月3日

.

。

About BioNTech

关于BioNTech

Biopharmaceutical New Technologies (BioNTech) is a global next generation immunotherapy company pioneering novel investigative therapies for cancer and other serious diseases. BioNTech exploits a wide array of computational discovery and therapeutic modalities with the intent of rapid development of novel biopharmaceuticals.

生物制药新技术公司（BioNTech）是一家全球下一代免疫治疗公司，开创了用于癌症和其他严重疾病的新研究疗法。BioNTech 利用广泛的计算发现和治疗模式，旨在快速开发新型生物制药。

Its diversified portfolio of oncology product candidates aiming to address the full continuum of cancer includes mRNA cancer immunotherapies, next-generation immunomodulators and targeted therapies such as antibody-drug conjugates (ADCs) and innovative chimeric antigen receptor (CAR) T cell therapies.

其多样化的肿瘤学候选产品组合旨在应对癌症的整个连续过程，包括mRNA癌症免疫疗法、下一代免疫调节剂和靶向疗法，如抗体药物偶联物（ADC）和创新的嵌合抗原受体（CAR）T细胞疗法。

Based on its deep expertise in mRNA development and in-house manufacturing capabilities, BioNTech and its collaborators are researching and developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global and specialized pharmaceutical collaborators, including Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech, a member of the Roche Group, Genmab, MediLink, OncoC4, Pfizer and Regeneron..

基于其在mRNA开发方面的深厚专业知识和内部生产能力，BioNTech及其合作伙伴正在研究和开发多种针对一系列传染病的mRNA疫苗候选产品，同时还有其多样化的肿瘤学管线。BioNTech已经与多家全球性和专业性制药合作伙伴建立了广泛的合作关系，其中包括百时美施贵宝、Duality Biologics、复星医药、罗氏集团成员基因泰克、Genmab、MediLink、OncoC4、辉瑞和再生元。

For more information, please visit

更多信息，请访问

www.BioNTech.com

www.BioNTech.com

.

。

Cautionary Statement Regarding Forward-Looking Statements

关于前瞻性陈述的谨慎声明

This document includes “forward-looking statements.” Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “look forward,” “investigational,” “pipeline,” “to acquire,” “development,” “to include,” “commitment,” or similar terms.

本文件包含“前瞻性声明”。前瞻性声明通常可以通过诸如“潜在”、“能够”、“将要”、“计划”、“可能”、“可以”、“会”、“预期”、“期待”、“研究性”、“管线”、“收购”、“开发”、“包括”、“承诺”或类似术语来识别。

Such forward-looking statements include, but are not limited to, statements relating to the Offer and other transactions contemplated by the purchase agreement, dated June 12, 2025, by and between BioNTech and CureVac (the “Purchase Agreement”), the benefits sought to be achieved in the transactions, the potential and capacity of BioNTech following the transaction, and the potential effects of the transactions on BioNTech and CureVac.

此类前瞻性声明包括但不限于与要约及2025年6月12日BioNTech与CureVac之间签署的购买协议（“购买协议”）所设想的其他交易相关的声明，这些交易寻求实现的利益、交易后BioNTech的潜力与能力，以及这些交易对BioNTech和CureVac的潜在影响。

Many of these risks and uncertainties are beyond the control of BioNTech or CureVac. Investors are cautioned that any such forward-looking statements are based on BioNTech’s current beliefs and expectations regarding future events and are not guarantees of future performance and involve risks and uncertainties.

许多此类风险和不确定性是 BioNTech 或 CureVac 无法控制的。投资者应注意，任何此类前瞻性陈述都是基于 BioNTech 对未来事件的当前信念和期望，而不是对未来业绩的保证，并且涉及风险和不确定性。

If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. You should not place undue reliance on these statements. .

如果基本假设被证明不准确或风险或不确定性成为现实，实际结果可能与前瞻性声明中所述的结果有重大差异。您不应过度依赖这些声明。

Risks and uncertainties include, but are not limited to, the effects of disruption from the transactions contemplated by the Purchase Agreement and the impact of the transactions on BioNTech’s business, including its relationships with employees, business partners or governmental entities; the outcome of any legal proceedings relating to the transactions; a diversion of management’s attention from ongoing business operations and opportunities as a result of the transactions contemplated by the Purchase Agreement or otherwise; general industry conditions and competition; general political, economic and business conditions, including interest rate, inflation, tariff and currency exchange rate fluctuations, and the ongoing Russia-Ukraine and Middle East conflicts; the impact of regulatory developments and changes in the United States, Europe and countries and regions outside of Europe, including with respect to tax matters; the impact of pharmaceutical industry regulation and health care legislation in the United States, Europe and elsewhere; the particular prescribing preferences of physicians and patients; competition from other products; challenges and uncertainties inherent in new product development; ability to obtain or maintain proprietary intellectual property protection; safety, quality, data integrity or manufacturing issues; and potential or actual data security and data privacy breaches.

风险和不确定性包括但不限于购买协议所设想的交易对BioNTech业务造成的中断影响，包括其与员工、商业伙伴或政府实体的关系；与这些交易相关的任何法律诉讼的结果；由于购买协议所设想的交易或其他原因导致管理层注意力从持续的业务运营和机会中分散；行业总体状况和竞争；总体政治、经济和商业环境，包括利率、通货膨胀、关税和汇率波动，以及持续的俄乌冲突和中东冲突；美国、欧洲及其他非欧洲国家和地区监管发展和变化的影响，尤其是在税务方面；美国、欧洲及其他地区制药行业监管和医疗保健立法的影响；医生和患者的特定处方偏好；来自其他产品的竞争；新产品开发固有的挑战和不确定性；获取或维持专有知识产权保护的能力；安全性、质量、数据完整性或制造问题；以及潜在或实际的数据安全和隐私泄露问题。

.

。

BioNTech does not undertake any obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by law. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in BioNTech’s Annual Report on Form 20-F for the year ended December 31, 2024, as amended by any subsequent filings made with the SEC, available on the SEC’s website at .

BioNTech 不承担任何公开更新任何前瞻性声明的义务，无论这是由于新信息、未来事件或其他原因，除非法律要求。可能导致结果与前瞻性声明中描述的情况有重大差异的其他因素，可参见 BioNTech 截至 2024 年 12 月 31 日的年度报告 Form 20-F，以及其后向美国证券交易委员会提交的任何修正文件，这些文件可在 SEC 的网站上查阅。

www.sec.gov

www.sec.gov

.

。

CONTACTS

联系人

Investor Relations

投资者关系

Douglas Maffei, Ph.D.

道格拉斯·马费伊，博士

Investors@BioNTech.de

投资者@BioNTech.de

Media Relations

媒体关系

Jasmina Alatovic

雅斯米娜·阿拉托维奇

Media@BioNTech.de

媒体@BioNTech.de